首页 > 最新文献

Personalized medicine最新文献

英文 中文
Association study of genetic polymorphisms in GABRD with treatment response and dose in methadone maintenance treatment. GABRD基因多态性与美沙酮维持治疗疗效和剂量的相关性研究。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-06-23 DOI: 10.2217/pme-2021-0063
Xiaohu Xie, Jun Gu, Dingding Zhuang, Xiaoyu Chen, Yun Zhou, Wenwen Shen, Longhui Li, Yue Liu, Wenjin Xu, Qingxiao Hong, Weisheng Chen, Wenhua Zhou, Huifen Liu

Aim: This study determined if gene variants in the GABA receptor delta subunit (GABRD) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin addiction. Materials & methods: A total of 286 MMT patients were recruited and divided into response and nonresponse groups based on retention time in therapy. A total of 177 responders were classified into low dose and high dose subgroups according to the stabilized methadone dose. Four (single nucleotide polymorphisms) SNPs (rs13303344, rs4481796, rs2376805 and rs2229110) in GABRD were genotyped using the TaqMan SNP assay. Logistic regression was used to assess the genetic effects of the SNPs in MMT. Results: No significant associations were observed between the SNPs and treatment response or dose, except the frequency of haplotype ACGC at the four SNPs significantly differed between responders and nonresponders. Conclusion: The results indicated that GABRD variants may play a small role in modulating methadone treatment response.

目的:本研究确定GABA受体δ亚基(GABRD)基因变异是否与美沙酮维持治疗(MMT)对海洛因成瘾的治疗反应和剂量相关。材料与方法:共招募286例MMT患者,根据治疗停留时间分为有反应组和无反应组。根据稳定的美沙酮剂量将177例应答者分为低剂量组和高剂量组。采用TaqMan SNP法对GABRD的4个单核苷酸多态性(rs13303344、rs4481796、rs2376805和rs2229110)进行基因分型。采用Logistic回归评估MMT中snp的遗传效应。结果:SNPs与治疗反应或剂量之间无显著相关性,除了四个SNPs的单倍型ACGC频率在应答者和无应答者之间有显著差异。结论:GABRD变异可能在调节美沙酮治疗反应中起较小作用。
{"title":"Association study of genetic polymorphisms in <i>GABRD</i> with treatment response and dose in methadone maintenance treatment.","authors":"Xiaohu Xie,&nbsp;Jun Gu,&nbsp;Dingding Zhuang,&nbsp;Xiaoyu Chen,&nbsp;Yun Zhou,&nbsp;Wenwen Shen,&nbsp;Longhui Li,&nbsp;Yue Liu,&nbsp;Wenjin Xu,&nbsp;Qingxiao Hong,&nbsp;Weisheng Chen,&nbsp;Wenhua Zhou,&nbsp;Huifen Liu","doi":"10.2217/pme-2021-0063","DOIUrl":"https://doi.org/10.2217/pme-2021-0063","url":null,"abstract":"<p><p><b>Aim:</b> This study determined if gene variants in the GABA receptor delta subunit (<i>GABRD</i>) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin addiction. <b>Materials & methods:</b> A total of 286 MMT patients were recruited and divided into response and nonresponse groups based on retention time in therapy. A total of 177 responders were classified into low dose and high dose subgroups according to the stabilized methadone dose. Four (single nucleotide polymorphisms) SNPs (rs13303344, rs4481796, rs2376805 and rs2229110) in <i>GABRD</i> were genotyped using the TaqMan SNP assay. Logistic regression was used to assess the genetic effects of the SNPs in MMT. <b>Results:</b> No significant associations were observed between the SNPs and treatment response or dose, except the frequency of haplotype ACGC at the four SNPs significantly differed between responders and nonresponders. <b>Conclusion:</b> The results indicated that <i>GABRD</i> variants may play a small role in modulating methadone treatment response.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"423-430"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39099313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Intelligent health system for the investigation of consenting COVID-19 patients and precision medicine. 新型冠状病毒肺炎患者自愿调查与精准医疗智能健康系统。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-10-08 DOI: 10.2217/pme-2021-0068
Zeeshan Ahmed

Advancing frontiers of clinical research, we discuss the need for intelligent health systems to support a deeper investigation of COVID-19. We hypothesize that the convergence of the healthcare data and staggering developments in artificial intelligence have the potential to elevate the recovery process with diagnostic and predictive analysis to identify major causes of mortality, modifiable risk factors and actionable information that supports the early detection and prevention of COVID-19. However, current constraints include the recruitment of COVID-19 patients for research; translational integration of electronic health records and diversified public datasets; and the development of artificial intelligence systems for data-intensive computational modeling to assist clinical decision making. We propose a novel nexus of machine learning algorithms to examine COVID-19 data granularity from population studies to subgroups stratification and ensure best modeling strategies within the data continuum.

推进临床研究前沿,我们讨论了智能卫生系统支持更深层次调查COVID-19的必要性。我们假设,医疗保健数据的融合和人工智能的惊人发展有可能通过诊断和预测分析来提升恢复过程,以确定死亡的主要原因、可改变的风险因素和可操作的信息,从而支持COVID-19的早期发现和预防。然而,目前的制约因素包括招募COVID-19患者进行研究;电子健康档案与多样化公共数据集的转化整合;以及开发用于数据密集型计算建模的人工智能系统,以协助临床决策。我们提出了一种新的机器学习算法关系,以检查从人口研究到子组分层的COVID-19数据粒度,并确保在数据连续体中采用最佳建模策略。
{"title":"Intelligent health system for the investigation of consenting COVID-19 patients and precision medicine.","authors":"Zeeshan Ahmed","doi":"10.2217/pme-2021-0068","DOIUrl":"https://doi.org/10.2217/pme-2021-0068","url":null,"abstract":"<p><p>Advancing frontiers of clinical research, we discuss the need for intelligent health systems to support a deeper investigation of COVID-19. We hypothesize that the convergence of the healthcare data and staggering developments in artificial intelligence have the potential to elevate the recovery process with diagnostic and predictive analysis to identify major causes of mortality, modifiable risk factors and actionable information that supports the early detection and prevention of COVID-19. However, current constraints include the recruitment of COVID-19 patients for research; translational integration of electronic health records and diversified public datasets; and the development of artificial intelligence systems for data-intensive computational modeling to assist clinical decision making. We propose a novel nexus of machine learning algorithms to examine COVID-19 data granularity from population studies to subgroups stratification and ensure best modeling strategies within the data continuum.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"573-582"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39495766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Creating accessible Spanish language materials for Clinical Sequencing Evidence-Generating Research consortium genomic projects: challenges and lessons learned. 为临床测序证据生成研究联盟基因组学项目创建无障碍西班牙语材料:挑战与经验教训。
IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-08-27 DOI: 10.2217/pme-2020-0075
Nangel M Lindberg, Amanda M Gutierrez, Kathleen F Mittendorf, Michelle A Ramos, Beatriz Anguiano, Frank Angelo, Galen Joseph

Aim: To increase Spanish speakers' representation in genomics research, accessible study materials on genetic topics must be made available in Spanish. Materials & methods: The Clinical Sequencing Evidence-Generating Research consortium is evaluating genome sequencing for underserved populations. All sites needed Spanish translation of recruitment materials, surveys and return of results. Results: We describe our process for translating site-specific materials, as well as shared measures across sites, to inform future efforts to engage Spanish speakers in research. Conclusion: In translating and adapting study materials for roughly 1000 Spanish speakers across the USA, and harmonizing translated measures across diverse sites, we overcame numerous challenges. Translation should be performed by professionals. Studies must allocate sufficient time, effort and budget to translate and adapt participant materials.

目的:为了提高西班牙语使用者在基因组学研究中的代表性,必须以西班牙语提供有关基因主题的易读研究材料。材料与方法:临床测序证据生成研究联盟正在评估服务不足人群的基因组测序。所有研究机构都需要将招募材料、调查问卷和结果反馈翻译成西班牙语。结果:我们介绍了我们翻译特定研究机构材料的过程,以及各研究机构的共享措施,以便为今后让讲西班牙语的人参与研究提供信息。结论在为全美大约 1000 名讲西班牙语的人翻译和改编研究材料,以及协调不同研究机构的翻译措施的过程中,我们克服了重重困难。翻译工作应由专业人员完成。研究必须分配足够的时间、精力和预算来翻译和调整参与者材料。
{"title":"Creating accessible Spanish language materials for Clinical Sequencing Evidence-Generating Research consortium genomic projects: challenges and lessons learned.","authors":"Nangel M Lindberg, Amanda M Gutierrez, Kathleen F Mittendorf, Michelle A Ramos, Beatriz Anguiano, Frank Angelo, Galen Joseph","doi":"10.2217/pme-2020-0075","DOIUrl":"10.2217/pme-2020-0075","url":null,"abstract":"<p><p><b>Aim:</b> To increase Spanish speakers' representation in genomics research, accessible study materials on genetic topics must be made available in Spanish. <b>Materials & methods:</b> The Clinical Sequencing Evidence-Generating Research consortium is evaluating genome sequencing for underserved populations. All sites needed Spanish translation of recruitment materials, surveys and return of results. <b>Results:</b> We describe our process for translating site-specific materials, as well as shared measures across sites, to inform future efforts to engage Spanish speakers in research. <b>Conclusion:</b> In translating and adapting study materials for roughly 1000 Spanish speakers across the USA, and harmonizing translated measures across diverse sites, we overcame numerous challenges. Translation should be performed by professionals. Studies must allocate sufficient time, effort and budget to translate and adapt participant materials.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"441-454"},"PeriodicalIF":1.7,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438935/pdf/pme-18-441.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39357000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of molecular biomarker tests: an interview study with healthcare providers about a molecular biomarker test for prostate cancer. 分子生物标志物测试的使用:一项关于前列腺癌分子生物标志物测试的医疗服务提供者访谈研究。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-08-06 DOI: 10.2217/pme-2020-0156
Karine Wendrich, Lotte Krabbenborg

Aim: Investigate why healthcare providers are not always willing to use molecular biomarker tests, even though they promise to personalize disease diagnosis and treatment. Materials & methods: We interviewed 20 Dutch urological healthcare providers to ascertain why they used or did not use SelectMDx, a biomarker test for prostate cancer. Results: Whether and how it was used differed from the developers' expectations, because users and nonusers disagreed about its perceived advantages; the scientific and clinical evidence; the advantages of MRI; and the value of PCA3 testing. Financial issues and the absence of SelectMDx in professional guidelines and hospital care pathways also hampered its use. Conclusion: Eliciting users' and nonusers' views is important to better understand how biomarker tests can be embedded in clinical practice.

目的:调查为什么医疗服务提供者不总是愿意使用分子生物标志物测试,即使他们承诺个性化疾病诊断和治疗。材料和方法:我们采访了20名荷兰泌尿科医疗保健提供者,以确定他们使用或不使用SelectMDx的原因,SelectMDx是一种前列腺癌的生物标志物测试。结果:是否和如何使用它与开发者的期望不同,因为用户和非用户不同意它的感知优势;科学和临床证据;MRI的优点;以及PCA3检测的价值。财政问题和专业指南和医院护理途径中没有SelectMDx也阻碍了它的使用。结论:征求使用者和非使用者的意见对于更好地理解如何将生物标志物检测嵌入临床实践非常重要。
{"title":"The use of molecular biomarker tests: an interview study with healthcare providers about a molecular biomarker test for prostate cancer.","authors":"Karine Wendrich,&nbsp;Lotte Krabbenborg","doi":"10.2217/pme-2020-0156","DOIUrl":"https://doi.org/10.2217/pme-2020-0156","url":null,"abstract":"<p><p><b>Aim:</b> Investigate why healthcare providers are not always willing to use molecular biomarker tests, even though they promise to personalize disease diagnosis and treatment. <b>Materials & methods:</b> We interviewed 20 Dutch urological healthcare providers to ascertain why they used or did not use SelectMDx, a biomarker test for prostate cancer. <b>Results:</b> Whether and how it was used differed from the developers' expectations, because users and nonusers disagreed about its perceived advantages; the scientific and clinical evidence; the advantages of MRI; and the value of <i>PCA3</i> testing. Financial issues and the absence of SelectMDx in professional guidelines and hospital care pathways also hampered its use. <b>Conclusion:</b> Eliciting users' and nonusers' views is important to better understand how biomarker tests can be embedded in clinical practice.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"471-482"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39279620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities. 组学技术在心血管疾病个性化联合治疗中的应用:挑战与机遇。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-10-25 DOI: 10.2217/pme-2021-0087
Saradindu Banerjee, Navya Prabhu Basrur, Padmalatha S Rai

The primary purpose of 'omics' technologies is to understand the intricacy of genomics, proteomics, metabolomics and other molecular mechanisms to reveal the complex traits of human diseases. The significant use of omics technologies and their applications in medicine gear up the study of the pathogenesis of several disorders. The detection of biomarkers in the early onset of diseases is challenging; still, omics can discover novel molecular mechanisms and biomarkers. In this review, the different types of omics and their technologies are explicated and aimed to provide their emerging applications in cardiovascular precision medicine. These technologies significantly impact optimizing medical treatment for individuals to reach a higher level in precision medicine.

“组学”技术的主要目的是了解基因组学、蛋白质组学、代谢组学和其他分子机制的复杂性,以揭示人类疾病的复杂特征。组学技术的大量使用及其在医学上的应用加快了对几种疾病发病机制的研究。在疾病早期检测生物标志物具有挑战性;然而,组学可以发现新的分子机制和生物标志物。本文综述了不同类型的组学及其技术,旨在为其在心血管精准医学中的应用提供参考。这些技术显著影响优化医疗个人达到更高水平的精准医疗。
{"title":"Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities.","authors":"Saradindu Banerjee,&nbsp;Navya Prabhu Basrur,&nbsp;Padmalatha S Rai","doi":"10.2217/pme-2021-0087","DOIUrl":"https://doi.org/10.2217/pme-2021-0087","url":null,"abstract":"<p><p>The primary purpose of 'omics' technologies is to understand the intricacy of genomics, proteomics, metabolomics and other molecular mechanisms to reveal the complex traits of human diseases. The significant use of omics technologies and their applications in medicine gear up the study of the pathogenesis of several disorders. The detection of biomarkers in the early onset of diseases is challenging; still, omics can discover novel molecular mechanisms and biomarkers. In this review, the different types of omics and their technologies are explicated and aimed to provide their emerging applications in cardiovascular precision medicine. These technologies significantly impact optimizing medical treatment for individuals to reach a higher level in precision medicine.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"595-611"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39568785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The role of metabolomics in personalized medicine for diabetes. 代谢组学在糖尿病个体化治疗中的作用。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-08-18 DOI: 10.2217/pme-2021-0083
Shamiha Chowdhury, Sultan Mohammed Faheem, Shaik Sarfaraz Nawaz, Khalid Siddiqui

Metabolomics is rapidly evolving omics technology in personalized medicine, it offers a new avenue for identification of multiple novel metabolic mediators of impaired glucose tolerance and dysglycemia. Liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy are most commonly used analytical methods in the field of metabolomics. Recent evidences showed that metabolomic profiles are link to the incidence of diabetes. In this review, an overview of metabolomics studies in diabetes revealed several diabetes-associated metabolites including 1,5-anhydroglycitol, branch chain amino acids, glucose, α-hydroxybutyric acid, 3-hydroundecanoyl-carnitine and phosphatidylcholine that could be potential biomarkers associated with diabetes. These identified metabolites can be used to develop personalized prognostics and diagnostic, and help in diabetes management.

代谢组学是个性化医疗中快速发展的组学技术,它为鉴定葡萄糖耐量受损和血糖异常的多种新型代谢介质提供了新的途径。液相色谱-质谱法、气相色谱-质谱法和核磁共振谱法是代谢组学领域最常用的分析方法。最近的证据表明,代谢组学特征与糖尿病的发病率有关。本文通过对糖尿病代谢组学研究的综述,揭示了几种与糖尿病相关的代谢物,包括1,5-无羟基甘油三酯、支链氨基酸、葡萄糖、α-羟基丁酸、3-羟基癸烷酰肉碱和磷脂酰胆碱,这些代谢物可能是与糖尿病相关的潜在生物标志物。这些鉴定的代谢物可用于发展个性化的预后和诊断,并有助于糖尿病的管理。
{"title":"The role of metabolomics in personalized medicine for diabetes.","authors":"Shamiha Chowdhury,&nbsp;Sultan Mohammed Faheem,&nbsp;Shaik Sarfaraz Nawaz,&nbsp;Khalid Siddiqui","doi":"10.2217/pme-2021-0083","DOIUrl":"https://doi.org/10.2217/pme-2021-0083","url":null,"abstract":"<p><p>Metabolomics is rapidly evolving omics technology in personalized medicine, it offers a new avenue for identification of multiple novel metabolic mediators of impaired glucose tolerance and dysglycemia. Liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy are most commonly used analytical methods in the field of metabolomics. Recent evidences showed that metabolomic profiles are link to the incidence of diabetes. In this review, an overview of metabolomics studies in diabetes revealed several diabetes-associated metabolites including 1,5-anhydroglycitol, branch chain amino acids, glucose, α-hydroxybutyric acid, 3-hydroundecanoyl-carnitine and phosphatidylcholine that could be potential biomarkers associated with diabetes. These identified metabolites can be used to develop personalized prognostics and diagnostic, and help in diabetes management.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"501-508"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life, death, genomics and psychiatry's struggle with esoteric disorders. 生命、死亡、基因组学和精神病学与深奥疾病的斗争。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-08-25 DOI: 10.2217/pme-2021-0020
Jan Dirk Blom, Brian A Sharpless
{"title":"Life, death, genomics and psychiatry's struggle with esoteric disorders.","authors":"Jan Dirk Blom,&nbsp;Brian A Sharpless","doi":"10.2217/pme-2021-0020","DOIUrl":"https://doi.org/10.2217/pme-2021-0020","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"417-421"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39341767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The integration of personalized medicine into health systems: progress and a path forward. 将个性化医疗纳入卫生系统:进展和前进道路。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-10-21 DOI: 10.2217/pme-2021-0102
Daryl Pritchard, Peter J Hulick, Christopher J Wells

Tweetable abstract Fueled by technological advancements and the integration efforts of many pioneer health systems, personalized medicine is now being clinically implemented at measurable but incomplete levels system-wide.

在技术进步和许多先锋卫生系统整合努力的推动下,个性化医疗目前正在全系统范围内以可衡量但不完整的水平进行临床实施。
{"title":"The integration of personalized medicine into health systems: progress and a path forward.","authors":"Daryl Pritchard,&nbsp;Peter J Hulick,&nbsp;Christopher J Wells","doi":"10.2217/pme-2021-0102","DOIUrl":"https://doi.org/10.2217/pme-2021-0102","url":null,"abstract":"<p><p>Tweetable abstract Fueled by technological advancements and the integration efforts of many pioneer health systems, personalized medicine is now being clinically implemented at measurable but incomplete levels system-wide.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"527-531"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39536009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
miR-938rs2505901 T>C polymorphism increases Hirschsprung disease risk: a case-control study of Chinese children. miR-938rs2505901 T>C多态性增加先天性巨结肠疾病风险:一项中国儿童病例对照研究
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-11-11 DOI: 10.2217/pme-2021-0001
Jun Zhong, Jiabin Liu, Yi Zheng, Xiaoli Xie, Qiuming He, Wei Zhong, Qiang Wu

Aim: To explore the association between miR-938rs2505901 T>C polymorphism and Hirschsprung disease (HSCR) risk in Chinese children. Materials & Methods: We conducted a case-control study in a Chinese population with 1381 cases and 1457 controls. The associated correlation strengths were assessed by adjusted odds ratios (AORs) and 95% CIs. Results: The results revealed that the rs2505901 TC and rs2505901 TC/CC genotype were related to an increased HSCR risk compared to the risk contributed by the rs2505901 TT genotype. A stratification analysis showed that the rs2505901 TC/CC genotype promoted the progression of HSCR more significantly in patients with the short-segment HSCR subtype. Conclusion: Our study indicated that miR-938rs2505901 T>C polymorphism is significantly associated with HSCR risk in Chinese children. This result needs to be confirmed with well-designed studies.

目的:探讨miR-938rs2505901 T>C多态性与中国儿童先天性巨结肠病(HSCR)风险的关系。材料与方法:我们在中国人群中进行了一项病例对照研究,共有1381例病例和1457例对照。通过校正优势比(AORs)和95% ci评估相关强度。结果:结果显示,与rs2505901 TT基因型相比,rs2505901 TC和rs2505901 TC/CC基因型与HSCR风险增加相关。分层分析显示,rs2505901 TC/CC基因型在短段HSCR亚型患者中更显著地促进HSCR的进展。结论:我们的研究表明miR-938rs2505901 T>C多态性与中国儿童HSCR风险显著相关。这一结果需要通过精心设计的研究来证实。
{"title":"<i>miR-938</i><i>rs2505901</i> T>C polymorphism increases Hirschsprung disease risk: a case-control study of Chinese children.","authors":"Jun Zhong,&nbsp;Jiabin Liu,&nbsp;Yi Zheng,&nbsp;Xiaoli Xie,&nbsp;Qiuming He,&nbsp;Wei Zhong,&nbsp;Qiang Wu","doi":"10.2217/pme-2021-0001","DOIUrl":"https://doi.org/10.2217/pme-2021-0001","url":null,"abstract":"<p><p><b>Aim:</b> To explore the association between <i>miR-938</i><i>rs2505901</i> T>C polymorphism and Hirschsprung disease (HSCR) risk in Chinese children. <b>Materials & Methods:</b> We conducted a case-control study in a Chinese population with 1381 cases and 1457 controls. The associated correlation strengths were assessed by adjusted odds ratios (AORs) and 95% CIs. <b>Results:</b> The results revealed that the <i>rs2505901</i> TC and <i>rs2505901</i> TC/CC genotype were related to an increased HSCR risk compared to the risk contributed by the <i>rs2505901</i> TT genotype. A stratification analysis showed that the <i>rs2505901</i> TC/CC genotype promoted the progression of HSCR more significantly in patients with the short-segment HSCR subtype. <b>Conclusion:</b> Our study indicated that <i>miR-938</i><i>rs2505901</i> T>C polymorphism is significantly associated with HSCR risk in Chinese children. This result needs to be confirmed with well-designed studies.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"551-558"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39610717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Defining the role of pharmacists in medication-related genetic counseling. 确定药剂师在药物相关遗传咨询中的作用。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2021-09-01 Epub Date: 2021-08-17 DOI: 10.2217/pme-2021-0005
Nova A Chart, David F Kisor, Christopher L Farrell

There is little question that precision medicine will eventually be the standard of care in treatment with algorithms designed for therapy selection and is already being used in some specialties such as cystic fibrosis and multiple cancer treatments. Genetic counselors are the heart of the treatment team in relation to counseling regarding genetic risk factors and disease states. A framework for treatment within the interdisciplinary team with more defined roles and areas of specialty will need to be in place as this practice approach expands with new data and treatments. Pharmacists are poised to be of great assistance in this matrix as many of these roles are merely an extension of current tasks and responsibilities of pharmacy practice.

毫无疑问,精准医疗最终将成为治疗的标准护理,其算法是为治疗选择而设计的,并且已经被用于一些专业,如囊性纤维化和多种癌症治疗。遗传咨询师是治疗团队的核心,涉及遗传风险因素和疾病状态的咨询。随着这种实践方法随着新数据和治疗方法的扩展,需要在跨学科团队中建立一个具有更明确角色和专业领域的治疗框架。药剂师准备在这个矩阵中提供很大的帮助,因为许多这些角色仅仅是当前药房实践任务和责任的延伸。
{"title":"Defining the role of pharmacists in medication-related genetic counseling.","authors":"Nova A Chart,&nbsp;David F Kisor,&nbsp;Christopher L Farrell","doi":"10.2217/pme-2021-0005","DOIUrl":"https://doi.org/10.2217/pme-2021-0005","url":null,"abstract":"<p><p>There is little question that precision medicine will eventually be the standard of care in treatment with algorithms designed for therapy selection and is already being used in some specialties such as cystic fibrosis and multiple cancer treatments. Genetic counselors are the heart of the treatment team in relation to counseling regarding genetic risk factors and disease states. A framework for treatment within the interdisciplinary team with more defined roles and areas of specialty will need to be in place as this practice approach expands with new data and treatments. Pharmacists are poised to be of great assistance in this matrix as many of these roles are merely an extension of current tasks and responsibilities of pharmacy practice.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"509-522"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39331150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Personalized medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1